Correction: Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part I: In Vitro Testing and Characterization.

Mohammad A M Momin, Dale Farkas, Michael Hindle, Felicia Hall, Robert M DiBlasi, Worth Longest

Abstract readPublished Erratum

In one paragraph

Article in Pharmaceutical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

Transnasal Administration of Surfactant Aerosol to the Lungs of Infants Using Direct Interfaces - Lessons Learned from Computational Fluid Dynamics.Pharmaceutical research · 2026
Article
Transnasal Administration of Surfactant Aerosol to the Lungs of Infants Using Direct Interfaces - Lessons Learned from Computational Fluid Dynamics.Pharmaceutical research · 2026
Article
Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants.AAPS PharmSciTech · 2025
Article
Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants.AAPS PharmSciTech · 2025
Article

4 · The record

Corrections and comments

Erratum for
Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part I: In Vitro Testing and Characterization.2024

5 · Who and what money

Authors and funding

6 authors.

Mohammad A M MominDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA.

Dale FarkasDepartment of Mechanical and Nuclear Engineering, Virginia Commonwealth University, 401 West Main Street, P.O. Box 843015, Richmond, Virginia, 23284-3015, USA.

Michael HindleDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA.

Felicia HallDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA.

Robert M DiBlasiCenter for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.

Worth LongestDepartment of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA. pwlongest@vcu.edu.ORCID http://orcid.org/0000-0003-4939-5691

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39237798

DOI10.1007/s11095-024-03760-9

PMCPMC11436437

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.